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A b s t r a c t
The role of oxidative stress in the onset and progression of atherosclerosis and its impact on the development of cardiovascular 
events has been widely described.
Thus, increased oxidative stress has been described in several atherosclerotic risk factors, such as hypertension, dyslipidaemia, 
peripheral artery disease, metabolic syndrome, diabetes, and obesity. 
Among others, specific oxidative pathways involving both pro-oxidant and antioxidant enzymes seem to play a major role in 
the production of reactive oxidant species (ROS), such as nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, 
myeloperoxidase, superoxide dismutase, and glutathione peroxidase.
In this review, we will discuss: 1) the most relevant enzyme systems involved in the formation and detoxification of ROS,  
2) the relationship between oxidative stress and cardiovascular risk, and 3) therapeutic implications to modulate oxidative stress. 
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INTRODUCTION
The term oxidative stress was coined by Sies [1] to describe 
a disturbance in the balance between reactive oxygen spe-
cies (ROS) production and antioxidant clearance. Currently, 
oxidative stress is defined as an event where a transient or 
permanent perturbation in the oxidative balance state gener-
ates physiological consequences within the cell, depending 
on the specific target and ROS concentrations. In physiologi-
cal conditions, ROS concentrations fluctuate in a controlled 
manner and are modulated by enzymatic and non-enzymatic 
antioxidant systems [2]. If this homeostatic state fails, such as in 
the case of hypertension, dyslipidaemia, diabetes, and obesity 
and acute conditions such as sepsis and respiratory failure, ROS 
levels increase [3, 4]. Also, xenobiotic triggers can influence 
the antioxidant status, among them: radiation, drugs, habits 
like smoking, and environmental agents. All these triggers can 
induce the synthesis and increase the activity of pro-oxidant 
enzymatic systems that are identified to be significantly in-
volved in the progression of the atherosclerotic disease [5]. 
In particular, nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidases and myeloperoxidase (MPO) are among the 
best established enzymatic systems involved in atherosclerotic 
progression [3] and are involved in the formation of ROS such 
as isoprostanes and superoxide anion (O2
–) [5].
Atherosclerosis is a chronic process of progressive hard-
ening and narrowing of arteries that reduces the flow and 
delivery of blood and oxygen throughout the body, leading 
to plaque formation [5]. It starts in childhood and progresses 
throughout life, with several risk factors favouring its pro-
gression [5]. Atherosclerotic plaque progression is caused by 
molecular changes induced by cytokines and ROS, mainly 
due to the interaction between endothelial cells, low-density 
lipoprotein (LDL), and macrophages. 
In particular, in the early stages of atherogenesis, LDLs are 
oxidised by ROS, giving formation to oxidised LDLs (oxLDLs), 
which are no longer cleared from sub-endothelial space and 
start to accumulate in the subendothelium [5]. Oxidised LDL 
activates the endothelium by inducing the production of adhe-
sion molecules, which recruit monocytes and T-cells, which are 
considered a key stimulator for the immune system response [5]. 
Monocytes differentiate into macrophages that internalise LDL 
and, along with T-cells, release pro-inflammatory cytokines and 
ROS to keep oxidising LDLs [5]. This contributes to the formation of 
an atherosclerotic plaque by apoptosis and foam cell formation [5].
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NADPH — nicotinamide adenine dinucleotide phosphate
Table 2. Nicotinamide adenine dinucleotide phosphate (NADPH) isoforms and localisation within vasculature
NADPH isoforms Vasculature distribution Product
NOX1 VSMCs, ECs Superoxide anion
NOX2 VSMCs, macrophages, fibroblasts, platelets, ECs Superoxide anion
NOX4 VSMCs, ECs, fibroblasts Hydrogen peroxide
NOX5 VSMCs, ECs Superoxide anion
ECs — endothelial cells; VSMCs — vascular smooth muscle cells
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These events lead to the formation of the so-called “fatty 
streak” and ultimately to atherosclerotic plaque [3]. Plaque 
rupture will induce platelet aggregation, coagulation cascade 
activation, and thrombus development and, as a conse-
quence, acute artery occlusion [3].
In this review, we will discuss 1) the most relevant enzyme 
systems involved in the formation and detoxification of ROS, 
2) the relationship between oxidative stress and cardiovascu-
lar risk, and 3) therapeutic implications for the treatment of 
atherosclerosis and its complications. 
OXIDATIVE STRESS AND ATHEROSCLEROSIS
An overview of pro- and anti-oxidant systems is provided in 
Table 1. Among the enzymatic systems involved in ROS for-
mation, a relevant role is played by NADPH oxidase (NOX), 
MPO, lipoxygenases (LOX), and uncoupled endothelial nitric 
oxide synthase (eNOS).
NADPH oxidase (Table 2) is an enzymatic system com-
posed of several subunits and different isoforms responsible 
for the formation of ROS, mostly O2
– and hydrogen peroxide 
(H2O2), that in turn are responsible for the formation of ac-
tive eicosanoids such as isoprostanes and thromboxanes [6]. 
The impact of the different NOX isoforms on the pro-
cess of human atherosclerosis is still a matter of debate. 
While the role of NOX2 in atherosclerosis initiation and 
progression has been widely described, other NOX isoforms 
seem to differently affect the atherosclerotic process. Thus, 
NOX1 and NOX5 are known to essentially elicit O2
– formation 
and to contribute to proliferation of human smooth muscle 
cells. NOX4 yields the formation of H2O2, which possesses 
vasodilating properties via eNOS activation. 
Several studies have demonstrated that the modulation 
of NADPH oxidase activity is associated with reduced risk of 
atherosclerotic disease. Apocynin, a compound that reduces the 
NADPH oxidase subunit p47phox translocation to the membrane 
subunit NOX2, inhibited atherosclerotic plaque formation in 
animals [7, 8]. Moreover, apocynin dose-dependently lowered 
total monocyte plaque accumulation, platelet adhesion, and 
atherosclerotic progression [7]. These data were supported in 
mice treated with a specific antibody blocking NADPH oxidase 
activity. Thus, Quesada et al. [8] found a significant regression 
of atherosclerotic plaque in mice fed with a high-fat diet and 
given a specific NOX2 inhibitor (NOX2ds-tat).
Experimental knock-out models of NADPH oxidases 
fully elucidated the role of NOX2 activity in athero-
sclerotic progression. Judkins et al. [9] studied a double 
knockout model of accelerated atherosclerosis repre-
sented by NOX2(–/y)/ApoE(–/–) mice, and found reduced 
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early lesion development in NOX2(–/y)/ApoE(–/–) animals com-
pared to ApoE(–/–) mice. Similar results were also obtained in 
ApoE(–/–)/p47phox(–/–) compared with ApoE(–/–) mice [10].
In human models over-expression of some NADPH oxi-
dase subunits was associated with accelerated atherosclerotic 
lesion progression. Thus, the hyper-expression of p22phox, the 
membrane-bound subunit of NADPH oxidase, was observed 
in the vessel wall of atherosclerotic coronary arteries using 
coronary sections from autopsied cases [11]. 
The human model of NADPH oxidase activity deletion, 
namely chronic granulomatous disease (CGD), permits 
confirmation of the central role of NADPH oxidase in the 
development of atherosclerotic diseases. CGD is prevalently 
characterised by NOX2 hereditary deficiency (X-linked) or, 
more rarely, by hereditary deficiency of p47phox subunit [12, 
13]. Patients with CGD disclosed lower cellular ROS formation 
in comparison to those with hereditary p47phox deficiency [13]. 
The interplay between NADPH oxidase and atherosclerosis 
was further studied in women carrying NOX2 deficiency [14]. 
Thus, Sibley et al. [15] compared CGD patients with control 
subjects and showed a 22% lower internal carotid artery wall 
volume with a similar reduction detected in both the p47phox- 
and gp91phox-deficient subtypes [15].
In addition to NOX2, MPO is fully represented within vulner-
able plaque, where it serves as an enzymatic source of oxidant 
species such as hypochlorous acid, chloramine, tyrosyl radicals, and 
nitrogen dioxide to generate atherogenic forms of both LDL and 
high-density lipoprotein (HDL) [16]. The ability of MPO-derived 
ROS to promote lipid peroxidation [17] is supported by an ex-
perimental study that showed that knockout mice for MPO had 
a reduction of F2-isoprostanes formation of about 85% [17].
Lipoxygenases play a significant role in the atherosclerotic 
process and are expressed in the vascular wall [18]. In particu-
lar, 5-LOX is expressed in human atherosclerotic plaques [19] 
and catalyses the transformation of free arachidonic acid into 
leukotriene B4 (LTB4), a potent chemo-attractant and leuko-
cyte activator [20]. Experiments in mice demonstrated that 
LTB4 antagonism by binding its specific receptor on the cell 
surface decreases foam cell translocation into the plaque [21]. 
Experiments on knockout models support the relevance of 
12/15-LOX in the atherosclerotic process. Thus, 12/15-LOX(–/–) 
mice on a high-fat diet presented reduced atherosclerosis, 
compared with control ApoE(–/–) mice [22]. 
The role of NOS is more controversial because it may act 
as a pro- and antioxidant system. Under normal conditions, 
eNOS exerts anti-atherogenic effects in the vascular wall [5], 
and in eNOS-deficient ApoE(–/–) mice an increased coronary 
atherosclerosis has been described [23]. 
On the contrary, eNOS becomes “uncoupled” in patho-
physiological conditions, resulting in the production of the 
pro-oxidant species O2
– by the transfer of electrons from 
NADPH through flavins to molecular oxygen and results in 
a pro-oxidant activity of eNOS [24]. 
Antioxidant enzyme systems
The vasculature is protected from excessive ROS formation 
by antioxidant enzyme systems, including superoxide dis-
mutases (SODs), catalase, glutathione peroxidases (GPxs), 
and paraoxonases (PONs) [3]. These systems protect against 
atherogenesis by scavenging ROS, facilitating endothelium-de-
pendent vasorelaxation, inhibiting inflammatory cell adhesion 
to endothelium, and altering vascular cellular responses, such 
as vascular smooth muscle cells (VSMCs) and endothelial cell 
apoptosis, VSMCs proliferation, hypertrophy, and migration. 
The SOD family is represented by three isoforms, namely 
SOD1, SOD2, and SOD3, which are able to protect against 
atherogenesis by converting O2
– into H2O2. Thus, overexpres-
sion of SOD1 delayed atherosclerotic lesion development in 
ApoE(–/–) mice [25], while SOD2 deficiency induced acceler-
ated atherosclerosis in the same animal model [26]. SOD1 and 
SOD2 deficiency results in VSMCs hyperplasia and hypertro-
phy mediated by different kinases [27]. Also, SOD3 displayed 
a protective effect; it was shown to prevent LDL oxidation 
in in-vitro experiments on rabbit endothelial cells [28, 29]. 
Eight isoforms of GPx have been described so far, but 
not all of them are well characterised. GPx1 is contained in 
red blood cells while GPx3 is the only circulating isoform. 
GPx seems to play a central role in protecting arterial walls 
from atherosclerotic progression by detoxifying intracellular 
H2O2 [30]. An increased atherosclerosis was observed in 
GPx1(–/–) mice [31], and the overexpression of GPx4 decreased 
atherosclerosis and delayed lesion progression in a similar 
animal model [32]. 
Paraoxonase, which exists in three isoforms (PON1, 
PON2, and PON3), is another antioxidant enzyme with 
atheroprotective effect. PON1 was shown to prevent LDL 
and HDL oxidation in vitro. PON1-knockout mice had higher 
levels of oxidised phospholipids compared with wild-type [33]. 
Furthermore, PON1 deficiency increased aortic atherosclero-
sis in wild-type and ApoE(–/–) mice [33, 34]. Similar results were 
obtained in PON2-deficient ApoE(–/–) mice, which disclosed 
increased mitochondrial oxidative stress and exacerbated 
atherosclerosis when fed with both chow and Western diet 
[35]. Finally, significantly smaller atherosclerotic lesions in 
PON3 transgenic mice were found in PON3-transgenic mice 
fed with an atherogenic diet [36].
OXIDATIVE STRESS RELATED  
TO CARDIOVASCULAR RISK FACTORS
Several cardiovascular risk factors such as type 2 diabetes mel-
litus (T2DM), hypertension, atrial fibrillation (AF), peripheral 
artery disease (PAD), obesity, metabolic syndrome (MetS), 
dyslipidaemia, habit of smoking, and pollution are associated 
with an increased production of ROS (Fig. 1) [37]. 
Urinary 8-iso-prostaglandin F2a (8-iso-PGF2a), which is 
derived from the non-enzymatic oxidation of arachidonic 
acid, and serum levels of soluble NOX2-derived peptide 
Figure 1. Relationship between cardiovascular risk factors and oxidative stress; Med-Diet — Mediterranean Diet; NOS — nitric 
oxide synthase; VSMCs — vascular smooth muscle cells
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(sNOX2-dp), a peptide released upon NOX2 activation, are 
among the most studied biomarkers of oxidative stress [14, 
38]. Urinary excretion of 8-iso-PGF2a is a validated and ac-
cepted reliable biomarker of in vivo oxidative stress, which 
has been investigated in healthy subjects and patients with 
cardiovascular diseases (CVDs) [39]. Useful markers of oxida-
tive stress are also MPO and oxLDL [39].
Increased values of urinary 8-iso-PGF2a [40] and serum 
sNOX2-dp levels as well as higher levels of MPO and oxLDL 
have been detected in subjects with or at risk for CVD, such 
as those with T2DM, obesity, PAD, hypercholesterolaemia, 
MetS, and hypertension.
A large body of evidence indicates that patients with 
T2DM have an increased ROS production, together with 
enhanced lipid peroxidation and isoprostane formation [41, 
42]. Of note, oxidative stress seems to be dependent upon 
glycaemic control. Thus, when analysing 62 non-insulin-de-
pendent DM subjects, urinary 8-iso-PGF2a excretion was 
seen to be significantly higher (419 ± 208 pg/mg creatinine) 
than in age-matched controls (208 ± 92 pg/mg creatinine; 
p < 0.001) [43]; the authors also observed that an improve-
ment in metabolic control was associated with a reduction 
in 8-iso-PGF2a levels (from 533 ± 276 to 365 ± 226 pg/mg 
creatinine; p = 0.001). Similarly, obese patients displayed 
increased urinary excretion of isoprostanes, as demonstrated 
by Davi et al. [44] when comparing 24 obese women to 
24 nonobese. Although numerous studies have documented 
an increased oxidative stress in obese subjects, the relation-
ship between the degree of obesity and systemic oxidative 
stress in humans is still an open question. No correlation at all, 
a positive correlation, or a link with obesity-related diseases 
have been described so far [45].
Isoprostanes and sNOX2-dp have also been investi- 
gated in patients affected by PAD. Compared to controls, 
PAD patients had increased sNOX2-dp (18.1 ± 17.6 
vs. 34.4 ± 21.2 pg/mL respectively; p < 0.001) and isopros-
tanes (126.9 ± 122.9 vs. 199.1 ± 130.4 pg/mg creatinine, 
respectively; p = 0.005) [46]. Also, MPO was evaluated in 
PAD patients. In a large cohort of 1324 African-Americans 
and 1237 non-Hispanic white individuals, high MPO was 
significantly associated with lower ankle-brachial index and 
the presence of PAD [47]. It should be taken into consider-
ation that, in addition to ROS formation, MPO contributes to 
oxidative stress by oxidising LDL and inactivating NO [48]. To 
confirm its central role in atherosclerotic progression the evi-
dence was derived from a prospective study. Thus, in a cohort 
of 156 PAD patients, MPO was an independent predictor of 
vascular outcomes including myocardial infarction (MI) and 
stroke for a value ≥ 183.7 pM [49].
Also, MetS is associated with increased levels of isopros-
tanes and oxLDL. Higher F2-isoprostanes were found in MetS 
patients (n = 30, 808 pmol/mmol creatinine) as compared 
to 30 controls balanced for age and sex (664 pmol/mmol 
creatinine; p = 0.05) [50]. Oxidised LDL [51], a key ele-
ment in the process of atherosclerosis, was evaluated in 
patients with MetS. Holvoet et al. [52] performed a large 
study on 3033 subjects: 1147 with and 1886 without MetS. 
The authors found elevated values of oxLDL in patients 
with MetS (1.45 ± 0.82 mg/dL) compared to those without 
(1.23 ± 0.67 mg/dL; p < 0.001). Hypercholesterolaemia 
is another risk factor with solid evidence as a trigger for ROS 
production. When comparing 40 hypercholesterolaemic 
adults to 40 matched controls, O2
–, a direct product of NADPH 
oxidase activation, was found to be increased and correlated 
to markers of platelet activation such as CD40 ligand [53]. This 
phenomenon seems to be involved in the early stages of the 
atherosclerotic disease initiation because similar results were 
found in children. Thus, compared to normocholesterolaemic 
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children, those with hypercholesterolaemia had higher MPO 
plasma levels that were associated with increased oxLDL [54]. 
Oxidative stress is also a critical component of hypertension, 
where NADPH oxidase represents the primary source of ROS. 
Mechanistically, angiotensin II, through angiotensin-1 receptor 
signalling, mediates the vascular up-regulation and activation 
of NADPH oxidase. In support of this is a study comparing the 
effect of the angiotensin II inhibitor irbesartan with diuretic 
therapy in hypertensive patients. Irbesartan-treated subjects 
presented lower level of O2
– [55]. 
Among the xenobiotic triggers for oxidative stress, smok-
ing and air pollution are critical risk factors associated with 
increased risk of cardiovascular event (CVE), and they are 
suggested to act by increasing ROS production. A recent re-
port identified air pollution within the top 10 risk factors for 
all-cause disease, greater than that caused by risk factors such 
as sedentary lifestyle or high cholesterol [56]. Both smoking 
and pollution result in the combustion of complex carbon-rich 
materials, with notable similarities in the compositions of 
these fumes. The biological pathways linking pulmonary 
exposure to these fumes and CVD development remain 
the subject of ongoing research, although oxidative stress is 
considered the most probable candidate in mediating these 
pathways [45]. Exposure to air pollution is accompanied by 
an increase in circulating oxidative stress markers. Thus, when 
investigating oxidative stress markers in 113 workers exposed 
to metal-rich particulate matters and 61 non-exposed vol-
unteers, plasma levels of soluble sNOX2-dp and 8-iso-PGF2a 
were found to be significantly increased in the exposed group 
[57]. Regarding smoking habit, analysis of oxidative biomark-
ers in a crossover, single-blind study performed in 40 healthy 
subjects (20 smokers and 20 non-smokers, matched for 
age and sex) demonstrated that among smokers, the use 
of electronic cigarettes was associated with lower levels of 
sNOX2-dp and urinary isoprostanes compared to regular 
tobacco smokers [58]. 
THE RELATIONSHIP BETWEEN OXIDATIVE 
STRESS AND CARDIOVASCULAR RISK
Human studies in subjects affected by genetic modification of 
ROS-producing enzymes such as NADPH oxidase and MPO 
suggest that they play a key role in the development of CVE. 
Thus, the C242T polymorphism in the gene for the p22phox 
subunit of NADPH oxidase was evaluated in 237 patients with 
coronary stenosis during a median follow-up of 7.8 years. The 
242T allele was found to be a predictor of lower risk of recur-
rence of CVE in high-risk patients and was associated with 
reduced systemic oxidative stress [59].
Similarly, individuals with total or subtotal MPO defi-
ciency or loss-of-function polymorphisms have presented 
a reduced rate of coronary heart disease (CHD) [60]. 
Several observational studies have supported the associa-
tion between oxidative stress and CVE. Solid evidence was 
found when analysing several pro-oxidant molecules such as 
8-iso-PGF2a and oxLDL and enzymes such as MPO. Plasma or 
urinary excretion of 8-iso-PGF2a has been extensively investi-
gated in patients with acute or chronic coronary artery disease 
(CAD). Cipollone et al. [61] measured 8-iso-PGF2a in urinary 
samples from patients with unstable angina (n = 32), stable an-
gina (n = 32), and from 40 healthy subjects. Urinary excretion 
of F2-isoprostanes in patients with unstable angina were higher 
(339 ± 122 pg/mg creatinine) compared to patients with 
stable angina (236 ± 83 pg/mg creatinine; p < 0.001) and 
in control subjects (192 ± 71 pg/mg creatinine; p < 0.001). 
In a further study, plasma levels of F2-isoprostanes were 
also significantly elevated in patients with angiographically 
documented CAD (n = 54), compared to controls (n = 50; 
9.0 ± 4.0 vs. 6.0 ± 3.0 µmol/mol; p < 0.001) [62]. Similarly, 
in a large case-control study, including 799 patients with 
CAD and 925 controls, Kim et al. [63] demonstrated that 
CAD patients had higher 8-epi-PGF2a compared to controls 
(1332.9 ± 29.4 vs. 1123.6 ± 20.1 pg/mg creatinine, respec-
tively; p < 0.001).
Of note, the levels of F2-isoprostanes were found to be 
associated with the number of affected vessels in a study in 
patients with angiographically proven CAD [64] and were 
confirmed also in a larger study in 241 subjects undergoing 
coronary angiography [65]. This evidence suggests a rela-
tionship between oxidative stress and the rate of coronary 
atherosclerosis. 
Also, the interplay between oxLDL and CVE was largely 
investigated. A cross-sectional study performed in CHD pa-
tients [66] investigated the association between oxLDL and 
the severity of CAD. The study included 63 acute coronary 
syndrome (ACS) patients, 35 patients with angiographic stable 
angina, 28 heart transplant patients with post-transplant CAD, 
79 heart transplant patients without CAD, and 65 control 
subjects. oxLDL levels were significantly higher in patients 
with CAD compared to those without CAD. Thus, plasma 
levels of oxLDL were 3.7-fold higher (p < 0.001) in patients 
with stable angina pectoris, 4.0-fold higher (p < 0.001) in 
patients with unstable angina pectoris, and 4.8-fold higher 
(p < 0.001) in patients with acute MI, compared to controls.
This data was corroborated by a second study on 135 pa-
tients with acute MI; in patients with MI (1.95 ± 1.42 ng/5 µg 
LDL protein), oxLDL levels were significantly higher than in 
patients with unstable (1.19 ± 0.74 ng/5 µg LDL protein; 
p < 0.0005) or stable angina (0.89 ± 0.48 ng/5 µg LDL 
protein; p < 0.001) or in 46 controls (0.58 ± 0.23 ng/5 µg 
LDL protein; p < 0.001) [67]. Taken together, these studies 
demonstrated that oxLDL levels correlated with the severity 
of ACS.
Several studies have investigated the relationship 
between MPO activity and CAD. In a first case-control 
study, leukocyte-MPO was significantly higher in 158 CAD 
patients (18.1 U/mg) in comparison to matched controls 
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(13.4 U/mg; p < 0.001) [68]. Similarly, in 384 patients 
presenting with ST-segment elevation MI, MPO was higher 
in patients experiencing death or non-fatal MI than in sur-
vivors (50.6 vs. 33.5 ng/mL; p = 0.001) [69]. MPO seems 
to play a role also in the development of heart failure. 
Thus, plasma MPO levels were elevated in patients with 
chronic systolic heart failure compared with healthy subjects 
(1158 ± 2965 vs. 204 ± 139 pM, respectively; p < 0.001). 
In this population, MPO levels increased in parallel with 
increasing functional New York Heart Association classes 
(p < 0.001) [70].
The predictive role of 8-iso-PGF2a has been tested by 
LeLeiko et al. [71] in 108 patients presenting with ACS with 
a significant increase of cardiac event rate across tertiles of 
F2-isoprostanes. The predictive power of 8-iso-PGF2a was 
also evaluated in patients affected by AF, in a large study 
that also tested the ability of sNOX2-dp to predict CVE. 
Analysing 1002 anticoagulated AF patients, a significant dif-
ference at baseline of median levels of urinary 8-iso-PGF2a 
(160 vs. 100 pg/mg creatinine; p < 0.001) and sNOX2-dp 
(13 vs. 9 pg/mL; p < 0.001) between patients with and without 
CVE was found [72]. In particular, a significant increase in the 
cumulative incidence of CVE and cardiovascular deaths was 
observed across tertiles for 8-iso-PGF2a and sNOX2-dp [72].
Also, MPO seems to be able to play a predictive role for 
CVE. A large study performed in 1090 patients with ACS 
with a six-month follow-up demonstrated that patients with 
elevated MPO levels (> 350 µg/L) had an increased risk of 
death and MI [73]. Another large study, which tested MPO 
activity in 604 consecutive patients presenting with chest 
pain at the emergency department, showed similar results 
[74]. Thus, the incidence of MI at 30 days increased with 
increasing quartiles of MPO levels, ranging from 13.9% 
in the first quartile (< 119.4 pM) to 38.4% in the fourth 
quartile (≥ 394.0 pM; p < 0.001 for trend). Similarly, 
above-median levels of MPO (> 55 ng/mL) predicted mor-
tality (odds ratio 1.8; p = 0.034) in 512 acute MI patients 
[75]. Also, data from the TACTICS-TIMI 18 trial support 
a predictive role for MPO. Studying 1524 ACS patients 
treated with tirofiban and randomised to early invasive or 
conservative management, the authors found that patients 
with elevated baseline MPO (> 884 pM) were at higher 
risk of non-fatal MI or re-hospitalisation for ACS at 30 days 
[76]. As opposed to 8-iso-PGF2a, sNOX2-dp and MPO that 
demonstrated a univocal capacity to predict CVE oxLDL 
presented divergent results.
In a prospective study on 238 patients with documented 
CAD, Shimada et al. [77] found that oxLDL levels were pre-
dictive of CVE in a follow-up of 52 months. Thus, the levels 
of circulating oxLDL were significantly higher in patients with 
CVE than in patients without (20.3 vs. 17.6 U/mL; p = 0.002).
A large study joining two different populations: 
18,140 men from the Health Professionals Follow-up Study 
and 32,826 women from the Nurses’ Health Study, confirmed 
the link between oxLDL and CVE. Hence, stratification of sub-
jects according oxLDL demonstrated that the highest quintile 
of oxLDL was significantly associated with an increased risk of 
CHD in a multivariate model [78]. Similar predictive power 
for CVE was found for oxLDL in the in the FRISC-II (Fragmin 
and fast Revascularisation during Instability in Coronary artery 
disease) trial, evaluating 433 patients with unstable CAD. 
OxLDL levels > 76 U/L were associated with a higher risk of 
recurrent MI at two years [79].
Conversely, data from the MONICA/KORA Ausburg 
study [80] demonstrated that oxLDL concentrations were 
not predicative for CVE. Although oxLDL levels were higher 
in 333 CHD cases compared with 1727 non-CHD subjects 
(103.3 vs. 87.8 U/L; p = 0.001), the predictive value of ox-
LDL became non-significant after adjustment for lipid profile. 
Similarly, in the Framingham offspring study, which meas-
ured immunoglobuline G antibodies to oxLDL in 1192 men 
and 1427 women with an eight-year follow-up, no association 
with CVE at follow-up was found [81]. It is arguable that the 
different methodology used in clinical studies may account for 
these conflicting results, but the value of oxLDL in predicting 
CVE should be further investigated.
ANTIOXIDANT STATUS  
AND CARDIOVASCULAR DISEASE
Reduced levels of antioxidant systems were associated with 
an increased risk for CVE; low levels of plasma SOD3 are 
independently associated with a history of MI in patients with 
CAD [82]. Also, a study on GPx3, an enzyme that catabolises 
hydrogen peroxide into water, supports this evidence. Thus, 
serum activities of GPx3, SOD, and catalase were measured 
in a prospective study on 900 AF patients, demonstrating 
that reduced levels of GPx3 increased the risk of CVE [83]. 
Among antioxidant vitamins, vitamins C and E have been 
the most widely investigated in observational and interven-
tional trials.
The WHO/MONICA (monitoring of trends and deter-
minants in cardiovascular disease) project found an inverse 
correlation between CHD mortality and vitamin E plasma 
levels [84]. Blood vitamin E levels predicted CVEs such as 
MI and stroke in 1012 elderly people affected by AF during 
27 months of follow-up [85]. Furthermore, Singh et al. [86] 
found that plasma levels of vitamins C and E were inversely 
related to CHD in a population of urban Indians. 
However, a large meta-analysis of interventional trials with 
vitamins C and E showed harmful effects such as enhanced 
risk of all-cause mortality or haemorrhagic stroke [87] in pa-
tients treated with antioxidants, compared to controls. These 
unexpected results could be due to several factors including 
selection of patients, dose of antioxidant, and antioxidant 
status at baseline. Conversely, no association was observed 
between CHD and other vitamins (vitamins A and C).
www.kardiologiapolska.pl
Oxidative stress and cardiovascular disease: new insights
719
THERAPEUTIC PERSPECTIVES  
AND CONCLUSIONS
Taken together, all data so far indicate the presence of an 
oxidative imbalance in several cardio-metabolic conditions, 
which is associated with an increased risk of ischaemic compli-
cations. However, no specific antioxidant treatment has been 
recommended so far to prevent atherosclerotic progression 
or CVEs, given the lack of randomised interventional trials. 
Thus, a first approach in the management of patients with, 
or at risk of, atherosclerotic complications should be repre-
sented by lifestyle interventions and nutritional counselling.
In this last context, the role of a healthy dietary pattern 
such as the Mediterranean Diet (Med-Diet) has been investi-
gated by several studies, giving promising results.
The Med-Diet is characterised by a high amount of foods 
rich in polyphenols such as fruit, vegetables, and extra-virgin 
olive oil (EVOO) and modest consumption of red wine. In the 
Lyon Diet Heart Study, the Med-Diet reduced cardiovascular 
complications by 50% in secondary prevention [88]. The 
PREDIMED trial [89], randomising 7447 people at high vas-
cular risk to the Med-Diet supplemented with EVOO, mixed 
nuts, or control diet [89], demonstrated that Med-Diet re-
duced the risk of CVD complications by 30% over a follow-up 
of about five years in the two arms supplemented with EVOO 
or nuts [89]. Consistent with this finding, we recently dem-
onstrated that adherence to the Med-Diet reduced the risk 
of CVE in patients affected by AF. Of note is that Med-Diet 
adherence was inversely correlated with sNOX2-dp and 
F2-isoprostanes [90]. Moreover, the Med-Diet is also associ-
ated with increased levels of the antioxidant GPx3, as was 
demonstrated in the same population of AF patients [91]. 
The inverse balance between antioxidants and pro-oxidants 
in patients at high adherence to the Med-Diet suggests that 
the Med-Diet can influence the CVE rate by modulating the 
oxidative imbalance. 
Similarly to the alimentary strategies, the efficacy of drugs 
in preventing CVE by modulating oxidative stress are attractive 
but still far from conclusive. These strategies are based on the 
principle of targeting specific oxidant pathways potentially 
implicated in atherothrombosis. Among them, an intriguing 
attractive approach could be represented by the inhibition of 
NOX2, which is up-regulated in the atherosclerotic process 
and is predictive of CVE [72].
However, a matter of concern is the role played by 
NOX2 in the innate system. A complete suppression of 
NOX2 activity is associated with serious life-threatening in-
fectious disease as depicted by the clinical history of patients 
with CGD [92]. It is interesting to note, however, that serious 
infection complications where not reported in the case of 50% 
reduction of NOX2 activity, as observed in NOX2 deficiency 
carriers [93]. Among the drugs modulating NOX2, statins 
represent a promising candidate because these drugs inhibit 
the activity of NOX2 subunit Ras-related C3 botulinum toxin 
substrate 1 [94]. Thus, in a randomised study in hypercholeste-
raemic patients, 40 mg atorvastatin ingestion was associated 
with immediate down-regulation of NOX2 [94]. Moreover, 
atorvastatin was also shown to reduce ROS formation during 
post-percutaneous coronary intervention reperfusion, impos-
ing a protective effect on the myocardial cell during ischae-
mic reperfusion injury [95]. Similar protective effects were 
obtained using rosuvastatin, another powerful lipid-lowering 
molecule [96]. However, prospective studies are needed to 
investigate if the protective effects of statins against CVD are 
also attributable to NOX2 inhibition. 
Another therapeutic option could be represented by apo-
cynin, which would have less negative impact on the innate 
immune system, as indicated by the more favourable clinical 
history of patients with hereditary deficiency of p47phox [97]. 
Few studies have analysed the effects of apocynin in humans 
[98–100]. In each study, apocynin administration for a few 
hours was well tolerated, but chronic systemic administration 
of apocynin in humans has never been tested. 
In conclusion, waiting for results from randomised inter-
ventional trials investigating new strategies to modulate oxi-
dative stress, lifestyle modifications, and nutritional approach 
should represent the first-line interventions to lower systemic 
oxidative stress in patients at risk of or with established athero-
sclerosis. Specifically, the Med-Diet is the only proven dietary 
pattern to be associated with lower levels of oxidative bio-
markers, and thus adherence to the Med-Diet should always 
be investigated in patients with cardio-metabolic diseases. 
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